Search hospitals > Illinois > Danville
Carle at The Riverfront
Claim this profileDanville, Illinois 61832
Global Leader in Thyroid Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Stomach Cancer
Conducts research for Uterine Tumors
194 reported clinical trials
12 medical researchers
Summary
Carle at The Riverfront is a medical facility located in Danville, Illinois. This center is recognized for care of Thyroid Cancer, Cancer, Breast Cancer, Stomach Cancer, Uterine Tumors and other specialties. Carle at The Riverfront is involved with conducting 194 clinical trials across 376 conditions. There are 12 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Suparna ManthaCarle Cancer Center5 years of reported clinical research
Studies Thyroid Cancer
Studies Stomach Cancer
35 reported clinical trials
78 drugs studied
Vamsi K. VasireddyCarle Cancer Center3 years of reported clinical research
Expert in Thyroid Cancer
Expert in Cancer
31 reported clinical trials
56 drugs studied
Maria T. Grosse-PerdekampCarle Cancer Center3 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
31 reported clinical trials
62 drugs studied
Kendrith Rowland, MDCarle Cancer Center8 years of reported clinical research
Studies Breast Cancer
Studies Thyroid Cancer
30 reported clinical trials
61 drugs studied
Clinical Trials running at Carle at The Riverfront
Lung Cancer
Breast Cancer
Thyroid Cancer
Breast cancer
Cancer
Prostate Cancer
Uterine Tumors
Ovarian Cancer
Stomach Cancer
Non-Small Cell Lung Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Carle at The Riverfront?
Carle at The Riverfront is a medical facility located in Danville, Illinois. This center is recognized for care of Thyroid Cancer, Cancer, Breast Cancer, Stomach Cancer, Uterine Tumors and other specialties. Carle at The Riverfront is involved with conducting 194 clinical trials across 376 conditions. There are 12 research doctors associated with this hospital, such as Suparna Mantha, Vamsi K. Vasireddy, Maria T. Grosse-Perdekamp, and Kendrith Rowland, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.